UAE Cardiovascular Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The uAE cardiovascular devices market size is estimated at USD 227.26 million in 2026, and is expected to reach USD 302.31 million by 2031, at a CAGR of 5.87% during the forecast period (2026-2031). This report is Segmented by Product Type (Diagnostic & Monitoring Devices, Therapeutic & Surgical Devices) and End User (Hospitals & Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Home Healthcare Settings). The Market Forecasts are Provided in Terms of Value (USD).

UAE Cardiovascular Devices Market Trends and Insights

Rising CVD Prevalence and Comorbidities

Cardiovascular disease claims 34% of all deaths and 70% of non-communicable disease mortality, magnified by obesity, hypertension, diabetes, and physical inactivity among residents. Mandatory annual cardiovascular screening for citizens over 40 will result in approximately half a million additional electrocardiograms, Holter monitors, and echocardiograms being incorporated into health-system workflows by 2028. The policy encourages hospitals to expand their diagnostic fleets while vendors bundle remote-monitoring services with implantable loop recorders, shifting revenue toward recurring software streams. Employers also fund workplace screening campaigns that rely on portable ultrasound and handheld electrocardiogram devices. These moves embed early-detection technology into primary care, broadening the user base and creating durable tailwinds for the UAE cardiovascular devices market.

Surge in Minimally Invasive Procedures and Device Innovation

Cleveland Clinic Abu Dhabi surpassed 500 transcatheter aortic valve implantations, underscoring a national shift from open surgery to percutaneous intervention. Boston Scientific’s FARAPULSE pulsed-field ablation reduces atrial-fibrillation procedure time by 40% and frees cath-lab schedules for additional cases. Edwards Lifesciences’ SAPIEN 3 Ultra RESILIA valve extends durability to about 15 years, encouraging use in younger cohorts. These advances reshape care pathways, reduce the length of stay, and increase throughput, thereby reinforcing equipment demand. Local manufacturing targets in the Dubai Industrial Strategy 2030 further quicken adoption by shortening supply chains and assuring hospitals of consistent inventory. Altogether, minimally invasive innovation accelerates procedure volumes and drives premium mix for the UAE cardiovascular devices market.

Stringent Approvals and High Procedure Costs

Device registration requires clinical-trial evidence, post-market plans, and Arabic labeling, demands that stretch smaller innovators without dedicated regulatory teams. The Essential Benefit Plan caps coverage at AED 150,000, leaving expatriates to self-fund implants, such as left ventricular assist devices, which cost USD 80,000 to USD 120,000. The Department of Health tariffs reimburse hospitals AED 45,000 for single-chamber pacemakers and AED 65,000 for dual-chamber systems. This spread is insufficient to offset the 20% price premium of MRI-conditional or leadless devices. Co-pays under the Basic Health Insurance Scheme reach 20%, pushing out-of-pocket costs above AED 13,000 for a TAVR case. These factors constrain demand for complex devices and temper the growth trajectory of the UAE cardiovascular devices market.

Other drivers and restraints analyzed in the detailed report include:

• Government Investment and Medical Tourism Positioning
• Import-Friendly Ecosystem for Global Majors
• Shortage of TAVR and EP Specialists and Cath-Lab Capacity

Segment Analysis

Therapeutic & Surgical Devices captured 64.71% of revenue in 2025, driven by an installed base of pacemakers, implantable cardioverter-defibrillators, and cardiac resynchronization systems that require periodic replacement, serving as a dependable engine for the UAE's cardiovascular devices market share. Diagnostic & Monitoring Devices, on the other hand, will expand at a 6.62% CAGR through 2031, thanks to remote monitoring pilots that have enrolled more than 15,000 patients, as well as mandatory annual screening for residents over 40. Within therapeutic devices, cardiac rhythm management dominates, as Cleveland Clinic Abu Dhabi implanted the country’s first leadless dual-chamber pacemaker in 2024, signaling a transition away from transvenous leads that can fracture or become infected. Catheters of all types are experiencing a surge in procedural growth; Al Qassimi Hospital alone logged 1,312 catheterizations in the first half of 2024. Drug-eluting balloon catheters are gaining a share in below-the-knee disease that once required stents.

Cardiac assist devices remain niche because transplant-related implants fall outside basic insurance, limiting volumes to a small group of well-insured Emiratis and medical tourists. Grafts serve open-heart cases that plateau as transcatheter options migrate into intermediate-risk cohorts. Diagnostic momentum, by contrast, stems from three forces. First, GE HealthCare’s USD 5,000 Vscan Air SL probe democratizes point-of-care ultrasound in family medicine clinics. Second, Mediclinic Middle East reduced heart-failure readmissions by 18% after integrating implantable cardioverter-defibrillator telemetry with Huma’s digital platform, demonstrating the value of continuous monitoring. Third, preoperative clearance protocols require electrocardiograms and echocardiograms, thereby integrating diagnostic workflows into routine surgical preparation. Taken together, diagnostics are accelerating faster than therapy volumes, thereby increasing the UAE cardiovascular devices market size for this category.

Complete Report Scope:

• By Product Type
  • Diagnostic & Monitoring Devices
    • Electrocardiogram
    • Remote Cardiac Monitoring
    • Other Diagnostic & Monitoring Devices
  • Therapeutic & Surgical Devices
    • Cardiac Assist Devices
    • Cardiac Rhythm Management Devices
    • Catheters
    • Grafts
    • Other Therapeutic & Surgical Devices
• By End User
  • Hospitals & Clinics
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Home Healthcare Settings

List of Companies Covered in this Report:

• Abbott Laboratories
• Advanced Healthcare
• Al Naghi Medical
• AngioDynamics
• Atlas Medical
• Becton Dickinson & Co.
• BIOTRONIK
• Boston Scientific
• Cardinal Health
• Cook Group
• Edwards LifeSciences
• GE Healthcare
• Johnson & Johnson
• Medtronic
• Koninklijke Philips
• Siemens Healthineers
• Terumo Corp.
• Vasmed UAE
• W. L. Gore & Associates

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support